source
- Alkermes reports Phase 3 success for Lumryz; Boehringer announces antibody partnershipAlkermes announced that its narcolepsy medication Lumryz, which received regulatory approval in 2023, achieved its primary efficacy endpoint in a Phase 3 trial. The study met the predefined criter…
- Eli Lilly suggests low-dose Zepbound and Foundayo could safely maintain weight loss at lower costNew trial data indicate that lowering the dose of Eli Lilly's obesity injection Zepbound may still provide effective weight‑loss maintenance while improving safety. The study also highlights Found…